Patients with metastatic and triple negative breast cancer appeared to have a lower mean age at diagnosis (51 vs. 57 years) and were less likely to have been previously treated for ovarian cancer (3% vs. 5%) compared to patients with metastatic and HER2(−) breast cancer (Additional file 1). The gene discussed is ERBB2; the disease is breast cancer.